Methods The Peptide Innovation for Early Diabetes Treatment (PIONEER) 12 trial was a randomised, double-dummy, active-controlled, parallel-group, Phase IIIa trial conducted over 26 weeks at 90 sites across the China region (including mainland China, Taiwan and Hong Kong) and five other countries
doi: 10.1053/j.gastro.2004.04.063 27 SmitsMMTonneijckLMuskietMHAKramerMHHCahenDLvan RaalteDH
Nutrients 9 (5), 511
Two Forms of CJC-1295 CJC-1295 exists in two clinically relevant forms: CJC-1295 with DAC (Drug Affinity Complex): This version includes a lysine linker that allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life to approximately 6-8 days
This approach requires close communication with your provider and is not appropriate for everyone
Processed Foods Why : Often loaded with sugar, salt, and unhealthy fats, processed foods can hinder your progress